--- title: "Wave Life Sciences (WVE) news: offering" url: "https://aibio.space/companies/wave-life-sciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "WVE offering news: Wave Life Sciences proposes $250,000,000 offering, then prices upsized $350 million deal. Wave Life Sciences, Inc." --- WVE Wave Life Sciences, Inc. NASDAQ · United States # Wave Life Sciences (WVE) news WVE offering news Listings · 2026-08-10 ## [Wave Life Sciences Ltd. (now Wave Life Sciences, Inc.) files Form 15 to end SEC reporting](https://aibio.space/news/wave-life-sciences-ltd-now-wave-life-sciences-inc-files-form-15-end/) The notice lists one holder of record of the ordinary shares and is dated August 7, 2026. Wave Life Sciences Ltd. reported a net loss of $204.4 million for 2025. ## Latest Wave Life Sciences news 1. 2026-04-15 Mergers [Wave Life Sciences plans to move its parent company from Singapore to Delaware](https://aibio.space/news/wave-life-sciences-plans-move-parent-company-singapore-delaware/) Wave Life Sciences said on April 15, 2026 that its board approved moving the parent company from Singapore to Delaware. Shares would be exchanged one for one, and the company expects the change in mid-2026, subject to shareholder and Singapore High Court approval. 2. 2025-12-08 Financings [Wave Life Sciences proposes $250,000,000 offering, then prices upsized $350 million deal](https://aibio.space/news/wave-life-sciences-proposes-250-000-000-offering-then-prices-upsized/) Wave Life Sciences filed a preliminary prospectus supplement on December 8, 2025 for a $250,000,000 offering. The pricing that followed on December 9 raised the deal to about $350 million at $19.00 per ordinary share. ## Wave Life Sciences at a glance - **Ticker**: WVE - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $430.7 million ### Related companies - [BioVie](https://aibio.space/companies/biovie/) NASDAQ: BIVI - [Cadrenal Therapeutics](https://aibio.space/companies/cadrenal-therapeutics/) NASDAQ: CVKD - [Nevis Brands](https://aibio.space/companies/nevis-brands/) CSE: NEVI - [IGC Pharma](https://aibio.space/companies/igc-pharma/) AMEX: IGC - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) NASDAQ: IOVA - [Recursion Pharmaceuticals](https://aibio.space/companies/recursion-pharmaceuticals/) NASDAQ: RXRX - [VirExit Technologies](https://aibio.space/companies/virexit-technologies/) OTC: VXIT - [Vincerx Pharma](https://aibio.space/companies/vincerx-pharma/) OTC: VINC ### Also on NASDAQ - [Unicycive Therapeutics](https://aibio.space/companies/unicycive-therapeutics/) UNCY - [ADMA Biologics](https://aibio.space/companies/adma-biologics/) ADMA - [Mereo BioPharma Group](https://aibio.space/companies/mereo-biopharma/) MREO - [NervGen Pharma](https://aibio.space/companies/nervgen-pharma/) NGEN - [DarioHealth](https://aibio.space/companies/dariohealth/) DRIO - [Caribou Biosciences](https://aibio.space/companies/caribou-biosciences/) CRBU ## Wave Life Sciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$182.8 million](https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/) | [$159.7 million](https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/) | | Net income (loss) | [-$204.4 million](https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/) | [-$97.0 million](https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/) | | Cash from operations | [-$187.5 million](https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/) | [-$151.0 million](https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/) | | Cash and equivalents | [$602.1 million](https://www.sec.gov/Archives/edgar/data/1631574/000119312526432714/) | [$302.1 million](https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1631574/000119312526432714/) | | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $197.3 million, plus short-term investments of $233.4 million, $430.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Wave Life Sciences Has Wave Life Sciences raised money recently? Our latest story on this, dated Dec 8, 2025: "Wave Life Sciences proposes $250,000,000 offering, then prices upsized $350 million deal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/wave-life-sciences-proposes-250-000-000-offering-then-prices-upsized/). What is the ticker symbol of Wave Life Sciences? Wave Life Sciences, Inc. trades under the ticker WVE on NASDAQ. Where is Wave Life Sciences listed? Wave Life Sciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0VS; LS:A42FEQ; LSX:A42FEQ. What is the SEC CIK of Wave Life Sciences? The SEC Central Index Key (CIK) for Wave Life Sciences, Inc. is 1631574. Its filings are on SEC EDGAR. How many shares does Wave Life Sciences have outstanding? 197,048,175 shares as of 2026-07-23, per the cover page of its 10-Q filed 2026-07-30. Which country or territory is Wave Life Sciences listed under? Our directory records Wave Life Sciences, Inc. under United States. What does Wave Life Sciences do? Our directory classifies Wave Life Sciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Wave Life Sciences? The ISIN recorded for Wave Life Sciences, Inc. is US94352A1043. Does aibio.space cover Wave Life Sciences? aibio.space lists Wave Life Sciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Wave Life Sciences incorporated? SEC records list its state or country of incorporation as DE. Is Wave Life Sciences profitable? Wave Life Sciences, Inc. reported a net loss of $204.4 million for the fiscal year ended Dec 31, 2025, and used $187.5 million of cash in operations, per its annual report to the SEC. How much does Wave Life Sciences spend on research and development? $182.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Wave Life Sciences have? $430.7 million in cash and short-term investments at Sep 30, 2026, per its 10-Q. What is the latest Wave Life Sciences (WVE) stock news? Our latest story on Wave Life Sciences, dated Aug 10, 2026: "Wave Life Sciences Ltd. (now Wave Life Sciences, Inc.) files Form 15 to end SEC reporting". The notice lists one holder of record of the ordinary shares and is dated August 7, 2026. Wave Life Sciences Ltd. reported a net loss of $204.4 million for 2025. [Source](https://aibio.space/news/wave-life-sciences-ltd-now-wave-life-sciences-inc-files-form-15-end/). Is Wave Life Sciences at risk of delisting? Our latest listing story, dated Aug 10, 2026: "Wave Life Sciences Ltd. (now Wave Life Sciences, Inc.) files Form 15 to end SEC reporting". The notice lists one holder of record of the ordinary shares and is dated August 7, 2026. Wave Life Sciences Ltd. reported a net loss of $204.4 million for 2025. [Source](https://aibio.space/news/wave-life-sciences-ltd-now-wave-life-sciences-inc-files-form-15-end/). ## Investor discussion: Wave Life Sciences Members talk about Wave Life Sciences (WVE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Wave Life Sciences, newest first. Each line links the filing it comes from. 1. 2026-08-10 Listings Filed to end its SEC reporting. SEC Form 15-12G. [Source](https://www.sec.gov/Archives/edgar/data/1631574/000119312526340683/d468186d1512g.htm) 2. 2026-04-15 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1631574/000119312526157003/d116643dex991.htm) 3. 2025-12-08 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1631574/000119312525311383/d16654d424b5.htm) 4. 2024-11-12 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1631574/000119312524255180/d865947ds3asr.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:WVE on TradingView](https://www.tradingview.com/symbols/NASDAQ-WVE/). ## SEC filings and registration - **SEC name**: Wave Life Sciences, Inc. - **CIK**: 1631574 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: WVE (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 733 CONCORD AVENUE, CAMBRIDGE, MA, 02138 - **Phone**: 617-949-2900 - **Shares outstanding**: 197,048,175 as of 2026-07-23 (10-Q filed 2026-07-30) - **Former names**: Wave Life Sciences Ltd.; Wave Life Sciences LTD.; WAVE Life Sciences Ltd. ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1631574/000119312526421806/d162196ddef14a.htm) filed 2026-10-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1631574/000119312526324949/wve-20260630.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/d177737d8k.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1631574/000119312526284002/d70732d8k.htm) filed 2026-06-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1631574/000119312526229076/d154261d8k.htm) filed 2026-05-18 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1631574/000119312526211828/d45078ddef14a.htm) filed 2026-05-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1631574/000119312526183587/wve-20260331.htm) filed 2026-04-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/d135689d8k.htm) filed 2026-04-28 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001631574), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Wave Life Sciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker WVE, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Wave Life Sciences, Inc. - **Ticker**: WVE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US94352A1043 - **Other listed symbols**: GETTEX:0VS; LS:A42FEQ; LSX:A42FEQ - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-WVE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/wave-life-sciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Wave Life Sciences (WVE) news: offering", 2026-10-31, https://aibio.space/companies/wave-life-sciences/